[go: up one dir, main page]

EA201991492A1 - ANTIBODIES TO LIF AND THEIR APPLICATION - Google Patents

ANTIBODIES TO LIF AND THEIR APPLICATION

Info

Publication number
EA201991492A1
EA201991492A1 EA201991492A EA201991492A EA201991492A1 EA 201991492 A1 EA201991492 A1 EA 201991492A1 EA 201991492 A EA201991492 A EA 201991492A EA 201991492 A EA201991492 A EA 201991492A EA 201991492 A1 EA201991492 A1 EA 201991492A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
lif
application
cancer
treatment
Prior art date
Application number
EA201991492A
Other languages
Russian (ru)
Inventor
Джон Сеоане Суарез
Джудит Анидо Фолгуэйра
Йохан Франссон
Жан-Филиппе Жулиен
Швета Раман
Original Assignee
Мозаик Биомедикалс, С.Л.Ю.
Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс
Фундасио Привада Институт Д'Инвестигасио Онкольохика Де Валь Эброн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мозаик Биомедикалс, С.Л.Ю., Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс, Фундасио Привада Институт Д'Инвестигасио Онкольохика Де Валь Эброн filed Critical Мозаик Биомедикалс, С.Л.Ю.
Priority claimed from PCT/IB2017/001677 external-priority patent/WO2018115960A1/en
Publication of EA201991492A1 publication Critical patent/EA201991492A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В настоящем документе описаны антитела, нацеленные на лейкоз-ингибирующий фактор (LIF). Также в настоящем документе описаны применения таких антител для лечения рака.Disclosed herein are antibodies targeting leukemia inhibitory factor (LIF). Also described herein are the uses of such antibodies for the treatment of cancer.

EA201991492A 2017-10-13 2017-12-18 ANTIBODIES TO LIF AND THEIR APPLICATION EA201991492A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382683 2017-10-13
PCT/IB2017/001677 WO2018115960A1 (en) 2016-12-19 2017-12-18 Antibodies against lif and uses thereof

Publications (1)

Publication Number Publication Date
EA201991492A1 true EA201991492A1 (en) 2020-04-23

Family

ID=60201972

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991492A EA201991492A1 (en) 2017-10-13 2017-12-18 ANTIBODIES TO LIF AND THEIR APPLICATION

Country Status (2)

Country Link
EA (1) EA201991492A1 (en)
PT (1) PT3555132T (en)

Also Published As

Publication number Publication date
PT3555132T (en) 2024-01-24

Similar Documents

Publication Publication Date Title
EA202092590A1 (en) PYRIDAZINONES AS PARP7 INHIBITORS
CY1123977T1 (en) ANTI-PD-1 AND ANTI-LAG3 ANTIBODIES FOR THE TREATMENT OF CANCER
CY1126855T1 (en) CYCLIC DINUCLEOTIDE COMPOUNDS FOR CANCER THERAPY
CY1123561T1 (en) COMPOUNDS USEFUL AS KINASE INHIBITORS
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
EA201891200A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
BR112018003269A2 (en) anti-dll3 drug-antibody conjugates and methods of use
MX385915B (en) ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS OF THESE
MX2021014286A (en) MULTISPECIFIC PROTEINS.
EA201990615A1 (en) Pyrrolobenzodiazepine conjugates
EA201790413A1 (en) ANTIBODIES AGAINST TIGIT
EA202092435A2 (en) MONOCLONAL ANTIBODIES AGAINST BCMA
EA201791867A1 (en) BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
EA201791046A8 (en) MACROCYCLIC PEPTIDES USED AS IMMUNOMODULATORS
MX2020007748A (en) Methods of treating cancers with antagonistic anti-pd-1 antibodies.
EA201692100A1 (en) NEW ANTIBODIES AGAINST RNF43 AND METHODS OF THEIR APPLICATION
EA201991997A1 (en) COMBINED THERAPY
BR112017004444A2 (en) new anti-mfi2 antibodies and methods of use
BR112018010279A2 (en) new anti-emr2 antibodies and methods of use
EA201892802A1 (en) Derivatives of adenosine for use in the treatment of cancer
EA201800148A1 (en) CHALLENGE VACCINE FOR CANCER TREATMENT
ZA201904533B (en) Antibodies against lif and uses thereof
MX389724B (en) PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS
EA201791391A1 (en) METHODS OF OBTAINING DIARYLTIOHYDANTOIN COMPOUND
BR112018012884A2 (en) new anti-mmp16 antibodies and methods of use